Protox Therapeutics Inc. Company Profile
Protox Therapeutics is a product-focused development-stage company and a leader in advancing novel, targeted protein toxin therapeutics for the treatment of cancer and other proliferative diseases. Through the company’s INxin™ and PORxin™ technology platforms, therapeutic candidates are generated by engineering the naturally occurring toxins, Pseudomonas exotoxin and proaerolysin. These drugs are potent anti-cancer agents with distinct modes of action.INxin™ drugs target cancer cells that produce specific tumor associated receptors on their cell surface. Once bound to the cancer cells, INxin™ drugs enter the cell and inhibit protein synthesis which ultimately leads to cell death. A Phase II clinical trial has been completed with Protox’s lead compound, PRX321, for the treatment of primary brain cancer, specifically recurrent malignant glioblastoma multiforme and astrocytoma. A Phase I clinical trial has also been completed for both renal cell carcinoma and non-small cell lung cancer. PRX321 is also in pre-clinical development for other peripheral solid tumors and hematological tumors
1210-885 West Georgia Street
Drugs and Medications
Protox Therapeutics is a product-focused development-stage company and a leader in advancing novel, targeted protein toxin therapeutics for the treatment of cancer and other proliferative diseases. Th...
More Information about "Protox Therapeutics Inc." on BioPortfolio
We have published hundreds of Protox Therapeutics Inc. news stories on BioPortfolio along with dozens of Protox Therapeutics Inc. Clinical Trials and PubMed Articles about Protox Therapeutics Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Protox Therapeutics Inc. Companies in our database. You can also find out about relevant Protox Therapeutics Inc. Drugs and Medications on this site too.